Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (5.378.299 €): Klinische Validierung eines KI-basierten Ansatzes zur Verbesserung des gemeinsamen Entscheidungsprozesses und der Ergebnisse bei Brustkrebspatientinnen, die für eine … Hor01.06.2022 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Klinische Validierung eines KI-basierten Ansatzes zur Verbesserung des gemeinsamen Entscheidungsprozesses und der Ergebnisse bei Brustkrebspatientinnen, die für eine lokoregionale Behandlung vorgeschlagen wurden
Breast cancer is the most commonly diagnosed cancer, with an estimated 2.3 million new cases per year globally. Approximately 90% of these patients will undergo breast surgery with/without radiation (locoregional treatment). Different surgical techniques can be offered to the patient, each leading to completely different aesthetic outcomes. Moreover, for different patients, undergoing the same surgery, the aesthetic outcome could be completely different based on individual patient's factors (e.g, age, body habitus). In the CINDERELLA project, we will be using the BreLO AI system (an artificial intelligence-based tool for classification of aesthetic outcomes and matching data and photographs) integrated in CANKADO (a cloud-based healthcare platform) to create an easy-to-use application that can be used on any electronic device, to simulate visually to the patient the aesthetic outcome of a certain surgery. The CINDERELLA APProach is unique as it uses a clinical database and performs biometric matching, to create images that simulate to the patient the outcome of surgery. In the CINDERELLA trial (running during the project) we plan to compare if the application helped to fulfil the expectation and lead to a better quality of life. By feeding new clinical and photographic information to the CINDERELLA APProach after surgery, the artificial intelligence platform will be able to improve for the next cases. This trial will be practice-changing in the field of patient education and shared decision making. CINDERELLA platform will help to overcome any miscommunication and potential boundaries in patient's or physician's understanding of the potential outcomes of locoregional treatment of breast cancer. We believe that the CINDERELLA APProach will be used in the future to other locoregional treatments that might change patients aesthetic appearance. Thus, CINDERELLA APProach will be the forerunner for new innovative tools for communicating with our patients.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Copernicus Podmiot Leczniczy sp. z o.o. | 103.500 € |
| Faculdade de Ciencias da Universidade de Lisboa | 0,00 € |
| Fciencias.ID - Associação para A Investigacao e Desenvolvimento de Ciencias | 295.362 € |
| Fundacao D. Anna de Sommer Champalimaud e DR. Carlos Montez Champalimaud | 1.066.750 € |
| Gdanski Uniwersytet Medyczny | 141.375 € |
| Inesc Tec - Instituto de Engenhariade Sistemas e Computadores, Tecnologia e Ciencia | 815.000 € |
| KRAFTVOLL TECHNOLOGIES GmbH | 802.000 € |
| MEDICAL RESEARCH INFRASTRUCTURE DEVELOPMENT AND HEALTH SERVICES FUND BY THE SHEBA MEDICAL CENTER | 392.292 € |
| Ospedale SAN Raffaele Srl | 681.310 € |
| Universita Commerciale Luigi Bocconi | 451.085 € |
| UNIVERSITATSKLINIKUM HEIDELBERG | 629.625 € |
Quelle: https://cordis.europa.eu/project/id/101057389
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.